CN109248319A - Contain the pharmaceutical composition for taking charge of smooth class compound and aspirin - Google Patents
Contain the pharmaceutical composition for taking charge of smooth class compound and aspirin Download PDFInfo
- Publication number
- CN109248319A CN109248319A CN201710572417.9A CN201710572417A CN109248319A CN 109248319 A CN109248319 A CN 109248319A CN 201710572417 A CN201710572417 A CN 201710572417A CN 109248319 A CN109248319 A CN 109248319A
- Authority
- CN
- China
- Prior art keywords
- aspirin
- class compound
- smooth
- take charge
- smooth class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 18
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 10
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 claims description 8
- 229960004399 carbocisteine Drugs 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- QLOBGRBOWVVKIE-NSHDSACASA-N (2r)-2-acetamido-3-(2-acetyloxybenzoyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=CC=C1OC(C)=O QLOBGRBOWVVKIE-NSHDSACASA-N 0.000 claims description 4
- FXPSJTKESYQXLX-HQVZTVAUSA-N (2r)-2-acetamido-3-(2-methyl-3-oxo-3-phenylpropyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSCC(C)C(=O)C1=CC=CC=C1 FXPSJTKESYQXLX-HQVZTVAUSA-N 0.000 claims description 4
- UGHACTSHTBCZGG-PHDIDXHHSA-N (4s)-3-[2-[[(2r)-2-sulfanylpropanoyl]amino]acetyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound C[C@@H](S)C(=O)NCC(=O)N1CSC[C@@H]1C(O)=O UGHACTSHTBCZGG-PHDIDXHHSA-N 0.000 claims description 4
- XVAYJUBRRZOANH-UHFFFAOYSA-N 2-(1,3-thiazolidine-3-carbonyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)N1CSCC1 XVAYJUBRRZOANH-UHFFFAOYSA-N 0.000 claims description 4
- DXSXAJGKYKXYMX-UHFFFAOYSA-N 2-[2-[(2-methyl-4-oxo-1,3-benzodioxin-2-yl)sulfanyl]propanoylamino]acetic acid Chemical compound C1=CC=C2OC(SC(C)C(=O)NCC(O)=O)(C)OC(=O)C2=C1 DXSXAJGKYKXYMX-UHFFFAOYSA-N 0.000 claims description 4
- MLLYDWHLZFTQBY-UHFFFAOYSA-N 3-(carboxymethylsulfanyl)propanoic acid Chemical compound OC(=O)CCSCC(O)=O MLLYDWHLZFTQBY-UHFFFAOYSA-N 0.000 claims description 4
- KINWYTAUPKOPCQ-YFKPBYRVSA-N Fudosteine Chemical compound OC(=O)[C@@H](N)CSCCCO KINWYTAUPKOPCQ-YFKPBYRVSA-N 0.000 claims description 4
- ULHWZNASVJIOEM-ZETCQYMHSA-N S-prenyl-L-cysteine Chemical compound CC(C)=CCSC[C@H](N)C(O)=O ULHWZNASVJIOEM-ZETCQYMHSA-N 0.000 claims description 4
- 229950001938 bencisteine Drugs 0.000 claims description 4
- 229950003369 cartasteine Drugs 0.000 claims description 4
- 229950002395 danosteine Drugs 0.000 claims description 4
- WSYVIAQNTFPTBI-UHFFFAOYSA-N ethyl 3-[2-[(2-methoxyphenoxy)methyl]-1,3-thiazolidin-3-yl]-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)N1CCSC1COC1=CC=CC=C1OC WSYVIAQNTFPTBI-UHFFFAOYSA-N 0.000 claims description 4
- 229950006783 fudosteine Drugs 0.000 claims description 4
- 229950006447 isalsteine Drugs 0.000 claims description 4
- IKOCLISPVJZJEA-UHFFFAOYSA-N letosteine Chemical compound CCOC(=O)CSCCC1NC(C(O)=O)CS1 IKOCLISPVJZJEA-UHFFFAOYSA-N 0.000 claims description 4
- 229960004870 letosteine Drugs 0.000 claims description 4
- 229950001125 midesteine Drugs 0.000 claims description 4
- 229950009623 moguisteine Drugs 0.000 claims description 4
- 229950009469 nesosteine Drugs 0.000 claims description 4
- 229950003826 prenisteine Drugs 0.000 claims description 4
- MKTVMEMIKNBVHI-UHFFFAOYSA-N s-[1-oxo-1-[(2-oxothiolan-3-yl)amino]propan-2-yl] thiophene-2-carbothioate Chemical compound C1CSC(=O)C1NC(=O)C(C)SC(=O)C1=CC=CS1 MKTVMEMIKNBVHI-UHFFFAOYSA-N 0.000 claims description 4
- 229950011165 salmisteine Drugs 0.000 claims description 4
- JJXDGYJCYKWEAI-UHFFFAOYSA-N taurosteine Chemical compound OS(=O)(=O)CCNC(=O)C1=CC=CS1 JJXDGYJCYKWEAI-UHFFFAOYSA-N 0.000 claims description 4
- 229950008172 taurosteine Drugs 0.000 claims description 4
- XBJWOGLKABXFJE-YFKPBYRVSA-N telmesteine Chemical compound CCOC(=O)N1CSC[C@H]1C(O)=O XBJWOGLKABXFJE-YFKPBYRVSA-N 0.000 claims description 4
- 229960002384 telmesteine Drugs 0.000 claims description 4
- JZKHUBWXBZINMO-UHFFFAOYSA-N 1,3-thiazinan-3-ium-4-carboxylate Chemical compound OC(=O)C1CCSCN1 JZKHUBWXBZINMO-UHFFFAOYSA-N 0.000 claims description 3
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
- 229960000830 captopril Drugs 0.000 claims description 3
- HSPYGHDTVQJUDE-LURJTMIESA-N dacisteine Chemical compound CC(=O)N[C@H](C(O)=O)CSC(C)=O HSPYGHDTVQJUDE-LURJTMIESA-N 0.000 claims description 3
- 229950007177 dacisteine Drugs 0.000 claims description 3
- 229960004635 mesna Drugs 0.000 claims description 3
- 229950008125 omonasteine Drugs 0.000 claims description 3
- 229950002628 guaisteine Drugs 0.000 claims description 2
- DUTQZUMFFDWHBC-UHFFFAOYSA-N s-[2-[2-[(2-methoxyphenoxy)methyl]-1,3-thiazolidin-3-yl]-2-oxoethyl] ethanethioate Chemical compound COC1=CC=CC=C1OCC1N(C(=O)CSC(C)=O)CCS1 DUTQZUMFFDWHBC-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 44
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 22
- 235000019359 magnesium stearate Nutrition 0.000 description 22
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 22
- 239000008108 microcrystalline cellulose Substances 0.000 description 22
- 229940016286 microcrystalline cellulose Drugs 0.000 description 22
- 239000002775 capsule Substances 0.000 description 20
- 239000007902 hard capsule Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 230000002776 aggregation Effects 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 210000004623 platelet-rich plasma Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940067132 aspirin 25 mg Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000025870 aspirin resistance Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229940085822 captopril 50 mg Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229960003262 erdosteine Drugs 0.000 description 1
- QGFORSXNKQLDNO-UHFFFAOYSA-N erdosteine Chemical compound OC(=O)CSCC(=O)NC1CCSC1=O QGFORSXNKQLDNO-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to preparing the application in the drug for preventing or treating cardiovascular and cerebrovascular disease containing the pharmaceutical composition and the pharmaceutical composition for taking charge of smooth class compound and aspirin.
Description
Technical field
The present invention relates to making containing the pharmaceutical composition and the pharmaceutical composition for taking charge of smooth class compound and aspirin
The application being ready for use in the drug of prevention or treatment cardiovascular and cerebrovascular disease.The invention belongs to pharmaceutical fields.
Background technique
Aspirin can effectively prevent cardiovascular and cerebrovascular disease, be current most popular medicament for resisting platelet aggregation.
However, having 8%~45% in research in recent years discovery medication crowd there are aspirin resistance, i.e. medication patient can still occur coronal
Arterial thrombus event or cerebral arterial thrombosis, and aspirin can cause serious risk of intracerebral hemorrhage in meeting is used for a long time
Increase.It is found and lists in spite of the drug of more new platelet aggregation-againsts, but all drugs remain medicine
Object effective dose and the increased contradiction of bleeding risk, also therefore can not to shake aspirin small in anti-blood for these new drugs
Plate assembles the classical status of diseases caused, these new drugs also drug combination of more options and aspirin in clinic
Or alternatively administered, to play the role of guaranteeing drug effect and reduce adverse reaction, for example, with sell better clopidogrel with
Aspirin combination medication, although both platelet aggregation inhibitors, drug combination drug effect is more preferable, while reducing by each
The dosage of antiplatelet drug reduces adverse reaction.
The smooth class drug of department for resolving sputum has more than 20 kinds, for example carbonyl first department is smooth, has good effect in terms of resolving sputum, closely
Fine application was had in a variety of diseases by Zhong Nanshan's discovery in several years, and has applied for that four related carbonyl first departments are smooth in new disease
Using patent.But it is not mentioned in relation to the smooth application in treatment disease as caused by platelet aggregation of carbonyl first department.
Summary of the invention
We always search for can with the compound of aspirin combination medication, while guaranteeing drug effect, reduce Ah
The every consumption per day for taking charge of a woods, to reduce adverse reaction.In primary unconscious trial, catching sight of carbocisteine has centainly
Inhibition platelet aggregation pharmacological action, it is contemplated that carbocisteine has the problem of adverse reaction of certain increase gastrorrhagia,
We select carbocisteine and aspirin combination for platelet aggregation-against, as a result, it has been found that the two drugs are inhibiting blood platelet
Aggregation aspect has good synergistic effect unexpectedly, can reduce aspirin dosage.Thus we are to more taking charge of smooth class chemical combination
Object carried out deeper into research, attempted the smooth class compound of department that 21 can obtain: mecrysteine, Fudosteine, strategic point
Take charge of more smooth, Moguisteine, Letosteine, dacisteine, Nesosteine, Midesteine, mesna, cartasteine, Taurosteine,
Danosteine, Salmisteine, Omonasteine, Prenisteine, Isalsteine, Bencisteine, captopril, Telmesteine and more wound department
It is smooth, and carry out pharmacy in vitro screening with rat plasma, it is found that these take charge of smooth class compound, all with inhibition platelet aggregation-against
Pharmacological action, only the strong and weak difference of effect is very big, it is contemplated that take charge of adverse reaction existing for smooth class compound, we select and
Aspirin combination medication finds that these are taken charge of smooth class compound and aspirin and have collaboration pharmacological action well.
Specific embodiment
Pharmacodynamics test 1:
Selective body focuses on 300 grams or more of adult rat, prepares 10% chloraldurate and passes through according to 280~350mg/kg dosage
Intraperitoneal injection of anesthesia, using abdominal aortic blood about 8~10ml, with 3.5% sodium citrate anticoagulant (blood and anti-coagulants volume
Than for 9: 1), being that 1000rpm is centrifuged 10min in centrifuge speed, separate platelet rich plasma (PRP)；3000rpm centrifugation
15min is separated platelet poor plasma (PPP).It uses PPP as substrate, is measured with PRP.170 microlitres are added in test cup
PPP sample and 30 microlitres of distilled water are put into TCH test channel, press PPP key and carry out substrate measurement；It is micro- that 170 are added in another test cup
PRP sample and 20 μ L drugs to be measured (final concentration of 100 μ g/ml, group, which is combined, respectively to be added into 100 μ g/ml aspirin) are risen, are added
Test cup is put into pre-temperature 2min in 37 DEG C of pre-temperature channels by one magnetic bead, after test cup moved into TCH test channel, by starting
Key is measured, and is added 10 microlitres of arachidonic acid (AA) inducer (making final concentration of 0.5mmol/l), and it is small to record blood in 5min
Plate maximum aggregation rate, and calculate its inhibiting rate.It is poly- to assemble inhibiting rate=(control group aggregation rate-test group aggregation rate)/control group
Collection rate × 100%, each test compound repeat experiment 5 times, and data processing takes mean to handle.
Experimental result is as follows:
Smooth class compound and aspirin combination medication are taken charge of to the inhibiting effect of platelet aggregation
Pharmacodynamics test 2:
Selective body focuses on 300 grams or more of adult rat, prepares 10% chloraldurate and passes through according to 280~350mg/kg dosage
Intraperitoneal injection of anesthesia, using abdominal aortic blood about 8~10ml, with 3.5% sodium citrate anticoagulant (blood and anti-coagulants volume
Than for 9: 1), being that 1000rpm is centrifuged 10min in centrifuge speed, separate platelet rich plasma (PRP)；3000rpm centrifugation
15min is separated platelet poor plasma (PPP).It uses PPP as substrate, is measured with PRP.170 microlitres are added in test cup
PPP sample and 30 microlitres of distilled water are put into TCH test channel, press PPP key and carry out substrate measurement；It is micro- that 177 are added in another test cup
PRP sample and 20 μ L drugs to be measured (final concentration of 100 μ g/ml, group, which is combined, respectively to be added into 100 μ g/ml aspirin) are risen, are added
Test cup is put into pre-temperature 2min in 37 DEG C of pre-temperature channels by one magnetic bead, after test cup moved into TCH test channel, by starting
Key is measured, and is added 3 microlitres of ADP inducer (making final concentration of 45mmol/ml), and blood platelet maximum aggregation in 5min is recorded
Rate, and calculate its inhibiting rate.Aggregation inhibiting rate=(control group aggregation rate-test group aggregation rate)/control group aggregation rate ×
100%, each test compound repeats experiment 5 times, and data processing takes mean to handle.
Experimental result is as follows:
Smooth class compound and aspirin combination medication are taken charge of to the inhibiting effect of platelet aggregation
Embodiment 1
It by carbocisteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, leads to after mixing
Tabletting machine is crossed, the tablet that every slice weight is 200mg is made.This tablet can be coated as needed.
Embodiment 2
It by captopril 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, leads to after mixing
Tabletting machine is crossed, the tablet that every slice weight is 200mg is made.This tablet can be coated as needed.
Embodiment 3
It by mecrysteine 25mg, aspirin 25mg, microcrystalline cellulose 140mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 4
It by Fudosteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 5
It by Erdosteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 6
It by Moguisteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 7
It by Letosteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 8
It by dacisteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 9
It by Nesosteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 10
It by Midesteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 11
It by mesna 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, is packed into after mixing
In hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 12
It by cartasteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 13
It by Taurosteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 14
It by danosteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 15
It by Salmisteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 16
It by Omonasteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 17
It by Prenisteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 18
It by Isalsteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 19
It by Bencisteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, is packed into after mixing
In hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 20
It by Telmesteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 21
It by guaisteine 50mg, aspirin 50mg, microcrystalline cellulose 90mg, magnesium stearate 10mg, is sieved, fills after mixing
Enter in hollow hard capsule, the capsule that every grain weight is 200mg is made.
Embodiment 22
By carbocisteine 50mg, aspirin 25mg, microcrystalline cellulose 115mg, magnesium stearate 10mg, it is sieved after mixing,
It is fitted into hollow hard capsule, the capsule that every grain weight is 200mg is made.
Claims (10)
1. a kind of medicine by taking charge of smooth class compound and aspirin combination for preventing and treating the disease as caused by platelet aggregation
Compositions, taking charge of smooth class compound and aspirin to take charge of smooth class compound/aspirin with mass ratio is 0.1~5 presence.
2. pharmaceutical composition described in claim 1, it is characterised in that: take charge of smooth class compound and aspirin to take charge of smooth class chemical combination
Object/aspirin is 0.5~2 presence with mass ratio.
3. pharmaceutical composition described in claim 1, it is characterised in that: take charge of smooth class compound and be selected from mecrysteine, Fudosteine, strategic point
Take charge of more smooth, Moguisteine, Letosteine, dacisteine, Nesosteine, Midesteine, mesna, cartasteine, Taurosteine,
Danosteine, Salmisteine, Omonasteine, Prenisteine, Isalsteine, Bencisteine, Telmesteine, captopril, more wound department
One of smooth and carbocisteine, including their pharmaceutically acceptable salt.
4. composition as claimed in claim 3, it is characterised in that: take charge of one of smooth class compound in danosteine and mecrysteine
Kind, including their pharmaceutically acceptable salt.
5. composition as claimed in claim 3, it is characterised in that: take charge of smooth class compound in Fudosteine and captopril
One kind, including their pharmaceutically acceptable salt.
6. composition as claimed in claim 3, it is characterised in that: take charge of smooth class compound and be selected from Prenisteine, Letosteine and reach
One of Xi Sitan, including their pharmaceutically acceptable salt.
7. composition as claimed in claim 3, it is characterised in that: take charge of smooth class compound and be selected from Nesosteine, Midesteine, U.S. department
One of sodium and cartasteine, including their pharmaceutically acceptable salt.
8. composition as claimed in claim 3, it is characterised in that: take charge of smooth class compound and be selected from Taurosteine, Salmisteine, Austria not
Take charge of one of smooth, Isalsteine, Moguisteine, Bencisteine, Telmesteine and guaisteine, including they pharmaceutically can be with
The salt of receiving.
9. composition as claimed in claim 3, it is characterised in that: take charge of smooth class compound be selected from carbocisteine or its pharmaceutically
Acceptable salt.
10. composition described in claim 2 and 9, it is characterised in that: the mass ratio of carbocisteine and aspirin is 1: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710572417.9A CN109248319A (en) | 2017-07-14 | 2017-07-14 | Contain the pharmaceutical composition for taking charge of smooth class compound and aspirin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710572417.9A CN109248319A (en) | 2017-07-14 | 2017-07-14 | Contain the pharmaceutical composition for taking charge of smooth class compound and aspirin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109248319A true CN109248319A (en) | 2019-01-22 |
Family
ID=65050990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710572417.9A Pending CN109248319A (en) | 2017-07-14 | 2017-07-14 | Contain the pharmaceutical composition for taking charge of smooth class compound and aspirin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109248319A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107157976A (en) * | 2017-07-03 | 2017-09-15 | 北京北朋科技有限公司 | Application of the compound of thioether acids structure in medicament for resisting platelet aggregation is prepared |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101385723A (en) * | 2007-09-11 | 2009-03-18 | 瑟维尔实验室 | Association between an anti-atherothrombotic and an angiotensin conversion enzyme inhibitor |
| CN101700248A (en) * | 2009-04-14 | 2010-05-05 | 青岛科技大学 | Preparation method of Aspirin and Captopril enteric sustained-release capsule |
| CN107157976A (en) * | 2017-07-03 | 2017-09-15 | 北京北朋科技有限公司 | Application of the compound of thioether acids structure in medicament for resisting platelet aggregation is prepared |
-
2017
- 2017-07-14 CN CN201710572417.9A patent/CN109248319A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101385723A (en) * | 2007-09-11 | 2009-03-18 | 瑟维尔实验室 | Association between an anti-atherothrombotic and an angiotensin conversion enzyme inhibitor |
| CN101700248A (en) * | 2009-04-14 | 2010-05-05 | 青岛科技大学 | Preparation method of Aspirin and Captopril enteric sustained-release capsule |
| CN107157976A (en) * | 2017-07-03 | 2017-09-15 | 北京北朋科技有限公司 | Application of the compound of thioether acids structure in medicament for resisting platelet aggregation is prepared |
Non-Patent Citations (3)
| Title |
|---|
| M TUTANC 等: "Effects of erdosteine on hemostasis: an experimental study", 《HUM EXP TOXICOL》 * |
| NISHIMORI T等: "GENERAL PHARMACOLOGICAL EFFECTS OF MESNA AND ITS METABOLITE DIMESNA", 《OYO Y AKURI》 * |
| RAY MOND L. HENRY等: "Mistabron Effects on Platelets and Blood Coagulation", 《J. INT. MEDRES》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107157976A (en) * | 2017-07-03 | 2017-09-15 | 北京北朋科技有限公司 | Application of the compound of thioether acids structure in medicament for resisting platelet aggregation is prepared |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2753523C2 (en) | Improved therapeutic index of inhibitors against immune checkpoint using combination therapy including phy906 extract, scutellaria baicalensis georgi (s) extract or compound of such extracts | |
| KR101869185B1 (en) | Glyt1 inhibitors for use in the treatment of hematological disorders | |
| CN107898782B (en) | A kind of ginkgo diterpenoid-lactone composition | |
| CN104758277A (en) | Uses of chlorogenic acid in preparation of drugs treating multidrug resistance of cancer | |
| UA127354C2 (en) | Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases | |
| US20210106542A1 (en) | Composition and method for inhibiting platelet aggregation | |
| TR201815685T4 (en) | Combinations of act and mec inhibitory compounds for the treatment of cancer. | |
| CN104958288B (en) | A kind of platelet suppressant drug and its application in antiplatelet disease medicament is prepared | |
| CN109248319A (en) | Contain the pharmaceutical composition for taking charge of smooth class compound and aspirin | |
| CN108853501B (en) | Application of magnetosensitive protein in improving neurodegenerative diseases | |
| TWI472519B (en) | N-butylidenephthalide-containing pharmaceutical composition for treating liver injury and improving liver function | |
| CN107157976A (en) | Application of the compound of thioether acids structure in medicament for resisting platelet aggregation is prepared | |
| Seelhammer et al. | Maintenance of drug-eluting stent patency through use of a cangrelor infusion in the clinical setting of massive pulmonary hemorrhage and venoarterial extracorporeal membrane oxygenation | |
| US11717511B2 (en) | Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer | |
| CN103417565B (en) | The application of depolymerization glycosaminoglycan extracted from sea cucumber in preparation control thrombotic diseases medicine | |
| Plotnikov et al. | Effect of n-tyrosol on blood viscosity and platelet aggregation | |
| KR20090082739A (en) | Composition Comprising Cordycepin for Inhibiting Migration and Proliferation of Vascular Smooth Muscle Cell | |
| KR20150102925A (en) | New hydroxysafflor yellow pharmaceutical salts | |
| Liao et al. | Successful large-volume leukapheresis for hematopoietic stem cell collection in a very-low-weight brain tumor infant with coagulopathy | |
| CN110604737A (en) | Application of triptonide | |
| US11684610B2 (en) | Pharmaceutical composition including 1,2-naphthoquinone derivative compound for prevention or treatment of solid cancers or blood cancers | |
| CN101816667B (en) | Application of forsythiaside A in preparation of drugs for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN104173334B (en) | A kind of pharmaceutical composition of antiplatelet aggregation | |
| CN114853715B (en) | Organic nitrite donor ketal type prodrug, preparation method and medical application thereof | |
| CN114191427B (en) | Medicine for inhibiting platelet activation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190122 |